Get Started Free
Home›Pharmaceuticals›Merck & Co.
Merck & Co. logo
Merck & Co.
Pharmaceuticals

Merck & Co. Company Overview

Merck & Co. logo

Merck & Co.

● Active
Pharmaceuticals · Rahway, NJ · Est. 1891
PharmaceuticalsOncologyVaccinesBiotechLife Sciences↗ Website
$285B
Valuation
$66.0B
Revenue
71k+
Employees
1891
Founded

Merck & Co. is a global biopharmaceutical company discovering, developing, and delivering innovative medicines and vaccines across oncology, infectious disease, cardiovascular, and immunology. Best known for Keytruda — the world's best-selling cancer immunotherapy — and Gardasil, the leading HPV vaccine, Merck serves patients in more than 140 countries through its pharmaceutical and animal health divisions.

Recent Press
5 items
Acquisition·2026-02-20
Merck Acquires Cidara Therapeutics for $9.2B to Expand Antiviral Portfolio
Merck completed the acquisition of Cidara Therapeutics for approximately $9.2 billion in 2026, gaining MK-1406, a long-acting strain-agnostic antiviral designed to prevent influenza in high-risk patients.
Press Release·2026-02-03
Merck Reports 2025 Results, Sets $70B Annual Sales Target for Next Decade
Merck reported strong full-year 2025 results and set an ambitious target of $70 billion in annual sales for next decade, backed by more than 25 regulatory approvals in major markets and an active M&A pipeline.
Acquisition·2026-01-15
Merck Acquires Terns Pharmaceuticals for $6.7B to Mitigate Keytruda Patent Cliff
Merck announced a $6.7 billion acquisition of Terns Pharmaceuticals, adding oncology pipeline assets designed to extend the company's cancer treatment leadership ahead of Keytruda's patent expiration in the late 2020s.
Product Launch·2025-07-15
Merck WINREVAIR Approved for Pulmonary Arterial Hypertension, Generates $200M
Merck received regulatory approval for WINREVAIR for pulmonary arterial hypertension and generated $200 million in sales in its launch year, establishing a new growth driver as the company diversifies beyond Keytruda.
Press Release·2025-06-13
FDA Approves KEYTRUDA for PD-L1+ Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Merck announced FDA approval of KEYTRUDA as the first perioperative anti-PD-1 treatment for resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, the first new approval in this indication in six years based on the KEYNOTE-689 trial.
Company History
10 milestones
George Merck established a U.S. affiliate of the German Merck KGaA in New York City in 1891, initially importing pharmaceutical chemicals from Germany. The U.S. entity became fully independent during World War I when the U.S. government seized German-owned assets in 1917, establishing Merck & Co. as an independent American pharmaceutical company.

Merck & Co. Organization Structure & Team

Org Chart
71,000 employees · Click a leader to explore their team
60,500 across 12 departments
Chief Executive Officer
Robert M. Davis
Caroline Litchfield — Departments
· 60500 people across 12 depts

Merck & Co. Financials, Revenue & Market Share

Annual Revenue
$66.0B
+4% vs prior year
YoY Growth
+4%
From $48.7B to $66.0B
Revenue / Employee
$896K
Annual revenue per full-time employee
Revenue Growth
2021
2022
2023
2024
2025
$48.7B
$59.3B
$58.5B
$63.6B
$66.0B
Market Share
Global Oncology Immunotherapy (PD-1/PD-L1)
14%
share
Merck & Co.
14%
Bristol-Myers Squibb
12%
AstraZeneca
12%
Roche/Genentech
11%
Pfizer
10%
$1.5T
TAM
$280B
SAM
$63.6B
SOM
Revenue Streams
Keytruda (Oncology)46%
Vaccines (Gardasil)12%
Hospital & Specialty18%
Primary Care & Other Pharmaceuticals15%
MSD Animal Health9%
Business Units
Innovative Medicines (Human Health)91%
Merck's core pharmaceutical segment encompassing prescription medicines and vaccines sold globally, dominated by Keytruda oncology revenues and the Gardasil vaccine franchise, with emerging growth from Winrevair and the Prometheus pipeline.
MSD Animal Health9%
Merck's animal health division providing vaccines, pharmaceuticals, and biologics for livestock, aquaculture, and companion animals — one of the world's largest animal health businesses with consistent double-digit growth.

Merck & Co. Internal Tools & Processes

Internal Tools
12 departments
Research & Early Discovery3800 people · 3 roles
Standards & Certifications
10 standards
Compliance frameworks, security audits, and quality certifications this company maintains.
Regulatory
FDA cGMP (21 CFR Parts 210/211)
Compliant
Merck's pharmaceutical manufacturing facilities worldwide operate under FDA Current Good Manufacturing Practice regulations (21 CFR Parts 210/211) governing the production, testing, and quality control of prescription drugs — including Keytruda biologics manufacturing at Merck's West Point, Pennsylvania and Rahway, New Jersey facilities.
Quality
ICH Q10 Pharmaceutical Quality System
Certified
Merck implements ICH Q10 pharmaceutical quality system principles across its global drug development and manufacturing operations, providing a harmonized framework for product and process knowledge management, quality risk management, and CAPA systems that aligns with FDA, EMA, and PMDA regulatory expectations.
Regulatory
EMA GMP (EU Annex 1)
Compliant
Merck's biologics and sterile drug manufacturing sites comply with European Medicines Agency GMP requirements including EU Annex 1 standards for sterile medicinal products — essential for Keytruda and Gardasil batch release into European markets where EMA inspects and certifies manufacturing sites independently of FDA.
Quality
ISO 15189 (Clinical Labs)
Certified
Merck's clinical diagnostic laboratories supporting companion diagnostic testing for Keytruda — including PD-L1 immunohistochemistry assays that guide patient selection — operate under ISO 15189 medical laboratory accreditation standards ensuring the accuracy and reliability of biomarker test results that inform oncology treatment decisions.
Privacy
HIPAA / GDPR (Clinical Trials)
Compliant
Merck complies with HIPAA Privacy and Security Rules and EU GDPR for patient health information collected across its global clinical trial portfolio of 1,000+ active studies, including Keytruda KEYNOTE trials and the Prometheus TL1A program — managing patient data sharing, informed consent, and cross-border data transfer under Standard Contractual Clauses.
Security
SOC 2 Type II
Certified
Merck's clinical data management and pharmacovigilance platforms — including the safety database systems used for Keytruda adverse event reporting and PADER submissions to FDA — maintain SOC 2 Type II certification to ensure the integrity and security of drug safety surveillance data supporting Merck's post-marketing commitments.
Regulatory
GCP (ICH E6)
Compliant
All of Merck's clinical trials — including the 1,600+ active KEYNOTE studies for Keytruda — are conducted in compliance with ICH E6 Good Clinical Practice guidelines, ensuring patient protection, data integrity, and the credibility of clinical evidence submitted to regulatory agencies worldwide for drug approval.
Environmental
ISO 14001
Certified
Merck's pharmaceutical manufacturing facilities hold ISO 14001 environmental management certification supporting the company's commitment to achieve carbon neutrality by 2025 for Scope 1 and 2 emissions and reduce Scope 3 value chain emissions 30% by 2030 — including solvent reduction, water recycling, and energy efficiency programs at the Rahway and West Point campuses.
Regulatory
FCPA Compliance Program
Compliant
Merck maintains a comprehensive Foreign Corrupt Practices Act compliance program governing interactions with healthcare professionals, government officials, and procurement agents across its 140+ country commercial operations — critically important for markets like China, Brazil, and Middle East where pharmaceutical marketing practices face heightened regulatory scrutiny.
Quality
USP/NF Pharmacopoeial Standards
Compliant
Merck's drug substances, excipients, and finished pharmaceutical products comply with United States Pharmacopeia and National Formulary (USP/NF) compendial standards, as well as Ph. Eur. (European Pharmacopoeia) and JP (Japanese Pharmacopoeia) standards for products sold in those markets — a baseline quality requirement for all marketed medicines.

Merck & Co. Interview Preparation

Interview Prep
Role-specific interview questions and keywords. Select a department, then click any role to prepare.
Research & Early Discovery· 3 roles

Merck & Co. Products & Competitors

Product Suite
5 products · select one to explore
Pharmaceuticals
Pharmaceutical
Keytruda (pembrolizumab)
The world's leading cancer immunotherapy.

Keytruda is Merck's anti-PD-1 immunotherapy that works by blocking the PD-1 pathway to help the immune system detect and fight tumor cells. Approved in over 40 indications including melanoma, non-small cell lung cancer, and triple-negative breast cancer, it is administered intravenously every 3–6 weeks at oncology infusion centers worldwide.

Use Cases
Treating first-line metastatic non-small cell lung cancer as monotherapy or in combination with chemotherapy based on PD-L1 expression testingAdjuvant treatment of resected stage IB–IIIA NSCLC to reduce recurrence risk following platinum-based chemotherapyCombination immunotherapy with Keytruda plus Lenvima (lenvatinib) for advanced endometrial carcinoma in MSI-H or TMB-H tumors
No image
Key Customers
MSK
Memorial Sloan Kettering
MDA
MD Anderson Cancer Center
MC
Mayo Clinic
Competitive Intelligence
VSOpdivo (Bristol Myers Squibb)
THEM

Opdivo (nivolumab) is BMS's anti-PD-1 checkpoint inhibitor approved across 15+ solid tumor and hematologic cancer types, often used in combination with Yervoy (ipilimumab) for dual checkpoint blockade.

EDGE

Broader label across more tumor types including NSCLC, melanoma, RCC, and bladder cancer with extensive combination data

VSTecentriq (Roche/Genentech)
THEM

Tecentriq (atezolizumab) is Roche's anti-PD-L1 checkpoint inhibitor approved for NSCLC, SCLC, and triple-negative breast cancer, with a mechanism targeting PD-L1 rather than PD-1.

EDGE

First-in-class PD-L1 inhibitor with established label in triple-negative breast cancer and small cell lung cancer

VSLibtayo (Regeneron/Sanofi)
THEM

Libtayo (cemiplimab) is a PD-1 inhibitor approved for cutaneous squamous cell carcinoma, basal cell carcinoma, and NSCLC, with a focused dermatologic oncology positioning.

EDGE

Strong positioning in cutaneous malignancies and favorable dosing schedule in CSCC

Related Companies

Pfizer logo
Pfizer
Pharmaceuticals
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines, vaccines, and consumer healthcare products across oncology, internal medicine, vaccines, and rare disease. It serves patients in over 125 countries through a portfolio spanning blockbuster drugs like Eliquis and Paxlovid to cutting-edge antibody-drug conjugates acquired through its $43B Seagen transaction.